2026年4月2日，东瑞制药(控股)有限公司（股票代码：02348）披露截至2026年3月31日的3月股份变动月报表。公告显示，公司于报告期末的法定股本维持在20,000,000,000股，每股面值0.05港元，总额1,000,000,000港元，较上个月无变化。
根据月报，公司本月已发行股份（不含库存股份）由上月末的1,503,557,000股增至1,503,605,000股，较上月增加48,000股。公告确认公司公众持股量符合相关要求，且月内并无新增库藏股或回购注销事项。
期权与激励计划方面，2026年3月共有48,000股因行使2013购股权计划而发行，截至月末该计划剩余8,580,000份未行使期权。本月行使期权共筹资43,200港元。2023购股权计划的期权数量整体维持不变。
公告称，公司在报告期内已遵循香港联交所《上市规则》及法律法规的要求完成所有股份发行事宜，并由董事会正式授权。该月报由公司秘书彭洁玲签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.